AU2003290363A1 - Therapeutic use of selective noradrenaline reuptake inhibitors - Google Patents

Therapeutic use of selective noradrenaline reuptake inhibitors

Info

Publication number
AU2003290363A1
AU2003290363A1 AU2003290363A AU2003290363A AU2003290363A1 AU 2003290363 A1 AU2003290363 A1 AU 2003290363A1 AU 2003290363 A AU2003290363 A AU 2003290363A AU 2003290363 A AU2003290363 A AU 2003290363A AU 2003290363 A1 AU2003290363 A1 AU 2003290363A1
Authority
AU
Australia
Prior art keywords
therapeutic use
reuptake inhibitors
noradrenaline reuptake
selective noradrenaline
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003290363A
Other versions
AU2003290363A8 (en
Inventor
John Gary Montana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paradigm Therapeutics Ltd
Original Assignee
Amedis Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0230135A external-priority patent/GB0230135D0/en
Priority claimed from GB0316203A external-priority patent/GB0316203D0/en
Application filed by Amedis Pharmaceuticals Ltd filed Critical Amedis Pharmaceuticals Ltd
Publication of AU2003290363A1 publication Critical patent/AU2003290363A1/en
Publication of AU2003290363A8 publication Critical patent/AU2003290363A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003290363A 2002-12-24 2003-12-23 Therapeutic use of selective noradrenaline reuptake inhibitors Abandoned AU2003290363A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0230135A GB0230135D0 (en) 2002-12-24 2002-12-24 Compounds and their uses
GB0230135.6 2002-12-24
GB0316203A GB0316203D0 (en) 2003-07-10 2003-07-10 Compounds and their use
GB0316203.9 2003-07-10
PCT/GB2003/005693 WO2004058353A2 (en) 2002-12-24 2003-12-23 Therapeutic use of selective noradrenaline reuptake inhibitors

Publications (2)

Publication Number Publication Date
AU2003290363A1 true AU2003290363A1 (en) 2004-07-22
AU2003290363A8 AU2003290363A8 (en) 2004-07-22

Family

ID=32683993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003290363A Abandoned AU2003290363A1 (en) 2002-12-24 2003-12-23 Therapeutic use of selective noradrenaline reuptake inhibitors

Country Status (2)

Country Link
AU (1) AU2003290363A1 (en)
WO (1) WO2004058353A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
MXPA05007379A (en) 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Method of treating nausea, vomiting, retching or any combination thereof.
AU2005238296A1 (en) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH385851A (en) * 1961-03-03 1964-12-31 Geigy Ag J R Process for the preparation of N-heterocyclic compounds
EP0319061A1 (en) * 1987-11-28 1989-06-07 Akzo N.V. Medicament with antiemetic action
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
CA2289190A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
EP1017695A4 (en) * 1997-09-26 2002-01-16 Univ Monash Resolution of optically-active compounds
MXPA02008183A (en) * 2000-02-24 2002-11-29 Upjohn Co New drug combinations.
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
EP1353675A2 (en) * 2001-01-02 2003-10-22 PHARMACIA & UPJOHN COMPANY New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
WO2002076461A1 (en) * 2001-03-26 2002-10-03 Serdar Murat Dursun Combination of reboxetine and citalopram

Also Published As

Publication number Publication date
WO2004058353A2 (en) 2004-07-15
WO2004058353A3 (en) 2004-09-23
AU2003290363A8 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
EP1496906A4 (en) Inhibitors of akt activity
EP1494675A4 (en) Inhibitors of akt activity
AU2003303128A1 (en) Inhibitors and methods of use thereof
IL173174A0 (en) Inhibitors of akt activity
EP1620095A4 (en) Inhibitors of akt activity
HK1077762A1 (en) INHIBITORS OF TFGβ
IL172063A0 (en) N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
EP1511488A4 (en) Human adam-10 inhibitors
AU2003214112A1 (en) Salts of nateglinide
AU2003277596A1 (en) Method of deuterization
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
AUPS160602A0 (en) Therapeutic method
AU2003292927A1 (en) Modified release formulations of selective serotonin re-uptake inhibitors
AU2003299815A1 (en) Matriptase inhibitors and methods of use
AU2003260778A1 (en) Treatment of pipes
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU2003234925A1 (en) TGF-Alpha EXPRESSION INHIBITORS
AU2002359177A1 (en) Use of interleukin-6 for treatment of obesity
PL373523A1 (en) Indol-2-ones as selective inhibitors of cyclooxygenase-2
GB0210741D0 (en) Methods of therapy
AU2003216848A1 (en) Deracemisation of amines
AU2003290363A1 (en) Therapeutic use of selective noradrenaline reuptake inhibitors
AU2002213830A1 (en) The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
AU2003238034A1 (en) Novel use of imidazotriazinones
AU2003236909A1 (en) Enabling use of encrypted data

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase